Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | MMP13 | P45452 | 2/20 | 0.56 |
| ▸ | PLK1 | P53350 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6768125 | 0.83 | SMYD3 (0.55) | HTTALDH1A1THRBMAPTMEN1 | |
| SCHEMBL13184545 | 0.79 | HPGD (1.00) | HPGDTSHRHTTSMN1; SMN2MMP13 | |
| SCHEMBL5955310 | 0.77 | HPGD (0.53) | HPGDTSHRSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL28967629 | 0.75 | PDE3B (0.53) | TSHRALDH1A1MAPTKMT2AKDM4E | |
| SCHEMBL14016637 | 0.73 | POLB (0.57) | SMN1; SMN2MAPTMEN1KMT2AKDM4E | |
| SCHEMBL6388803 | 0.73 | HPGD (0.85) | HPGDTSHRHTTSMN1; SMN2MMP13 | |
| SCHEMBL5375128 | 0.73 | HPGD (0.85) | HPGDTSHRHTTSMN1; SMN2MMP13 | |
| SCHEMBL6252549 | 0.73 | HPGD (0.85) | HPGDTSHRHTTSMN1; SMN2MMP13 | |
| SCHEMBL8737710 | 0.73 | MMP13 (1.00) | HPGDTSHRHTTSMN1; SMN2MMP13 | |
| SCHEMBL12228182 | 0.72 | MMP13 (0.81) | HPGDTSHRHTTSMN1; SMN2MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111315735-A | Dihydrobenzimidazolones | C4医药公司 | 2020-06-19 | — | — | CN | claimed |
| US-12365681-B2 | Dihydrobenzimidazolones for medical treatment | C4 THERAPEUTICS, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| CN-118206529-A | Dihydrobenzimidazolone | C4医药公司 | 2024-06-18 | — | — | CN | disclosed |
| US-20240109889-A1 | DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | US | disclosed |
| CN-111315735-B | Dihydrobenzimidazolone | C4医药公司 | 2024-03-08 | — | — | CN | disclosed |
| US-11787802-B2 | Dihydrobenzimidazolones for medical treatment | C4 THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787802-B2 | Dihydrobenzimidazolones for medical treatment | C4 THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787802-B2 | Dihydrobenzimidazolones for medical treatment | C4 THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20220289738-A1 | DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2022-09-15 | — | — | US | disclosed |
| US-20220289738-A1 | DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2022-09-15 | — | — | US | disclosed |
| US-11254672-B2 | Dihydrobenzimidazolones for medical treatment | C4 THERAPEUTICS, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| US-11254672-B2 | Dihydrobenzimidazolones for medical treatment | C4 THERAPEUTICS, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| EP-3679027-A1 | DIHYDROBENZIMIDAZOLONES | C4 Therapeutics, Inc. (US) | 2020-07-15 | — | — | EP | disclosed |
| US-20200207764-A1 | DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2020-07-02 | — | — | US | disclosed |
| US-20200207764-A1 | DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2020-07-02 | — | — | US | disclosed |
| CN-111315735-A | Dihydrobenzimidazolones | C4医药公司 | 2020-06-19 | — | — | CN | disclosed |
| WO-2019043217-A1 | DIHYDROBENZIMIDAZOLONES | F. HOFFMANN-LA ROCHE AG (CH) | 2019-03-07 | — | — | WO | disclosed |
| WO-2019043217-A1 | DIHYDROBENZIMIDAZOLONES | F. HOFFMANN-LA ROCHE AG (CH) | 2019-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200207764-A1 | DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT | CRBN, CUL4A, ADRM1 | HPGD 3006/4885TSHR 3866/4885HTT 3025/4885 |
| US-12365681-B2 | Dihydrobenzimidazolones for medical treatment | CRBN, CUL4A, ADRM1 | HPGD 3006/4885TSHR 3866/4885HTT 3025/4885 |
| US-20240109889-A1 | DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT | CRBN, CUL4A, ADRM1 | HPGD 3006/4885TSHR 3866/4885HTT 3025/4885 |
| US-20220289738-A1 | DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT | CRBN, CUL4A, ADRM1 | HPGD 3006/4885TSHR 3866/4885HTT 3025/4885 |
| US-11787802-B2 | Dihydrobenzimidazolones for medical treatment | CRBN, CUL4A, ADRM1 | HPGD 3006/4885TSHR 3866/4885HTT 3025/4885 |
| US-11254672-B2 | Dihydrobenzimidazolones for medical treatment | CRBN, CUL4A, ADRM1 | HPGD 3006/4885TSHR 3866/4885HTT 3025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.